Effects of a Hemp Seed-based Product on Appetite and Health Parameters
NCT07917130, Not applicable, Recruiting, Halic University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of a Hemp Seed-based Product on Appetite and Health Parameters | ClinicalTrials.gov |
| NCT number | NCT07917130 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 70 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Halic University | ClinicalTrials.gov |
| Conditions | Healthy | ClinicalTrials.gov |
| Interventions | hempseed snack, control snack | ClinicalTrials.gov |
| First posted | 2026-11-04 | ClinicalTrials.gov |
| Last updated | 2026-11-04 | ClinicalTrials.gov |
Registered outcomes 20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change from Baseline in Hunger Score | Baseline (Week 0), Week 2, Week 4, Week 6, and Week 8. | Hunger will be assessed using a 100-mm (10 cm) Visual Analog Scale (VAS), ranging from 0 to 100 mm (10 cm). Higher scores indicate greater subjective hunger. Hunger: 0 = Not hungry at all, 100 = Extremely hungry. | ClinicalTrials.gov |
| Primary | Change from Baseline in Fullness Score | Baseline (Week 0), Week 2, Week 4, Week 6, and Week 8. | Subjective fullness will be assessed using a 100-mm (10 cm) Visual Analog Scale (VAS), ranging from 0 to 100 mm (10 cm). Higher scores indicate greater subjective fullness. Fullness: 0 = Not full at all, 100 = Extremely full. | ClinicalTrials.gov |
| Primary | Change from Baseline in Desire to Eat Score | Baseline (Week 0), Week 2, Week 4, Week 6, and Week 8. | Desire to eat will be assessed using a 100-mm (10 cm) Visual Analog Scale (VAS), ranging from 0 to 100 mm (10 cm). Higher scores indicate a greater desire to eat. Desire to Eat: 0 = No desire to eat, 100 = Extremely strong desire to eat. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Body Weight | Baseline (Week 0), Week 2, Week 4, Week 6, and Week 8. | Body weight will be measured in kilograms (kg) using the Tanita BC-418 body composition analyzer. Changes in body weight from baseline throughout the intervention will be evaluated. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Body Mass Index (BMI) | Baseline (Week 0), Week 2, Week 4, Week 6, and Week 8. | Body mass index (BMI) will be calculated using body weight measured with the Tanita BC-418 body composition analyzer and height measured using a stadiometer. BMI will be calculated as body weight in kilograms divided by height in meters squared (kg/m²). Changes in BMI from baseline throughout the intervention will be evaluated. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Body Fat Percentage | Baseline (Week 0), Week 2, Week 4, Week 6, and Week 8. | Body fat percentage will be assessed using bioelectrical impedance analysis (BIA) with the Tanita BC-418 body composition analyzer and expressed as a percentage (%). Changes in body fat percentage from baseline throughout the intervention will be evaluated. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Fat Mass | Baseline (Week 0), Week 2, Week 4, Week 6, and Week 8. | Fat mass will be assessed using bioelectrical impedance analysis (BIA) with the Tanita BC-418 body composition analyzer and expressed in kilograms (kg). Changes in fat mass from baseline throughout the intervention will be evaluated. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Fat-Free Mass | Baseline (Week 0), Week 2, Week 4, Week 6, and Week 8. | Fat-free mass (FFM) will be assessed using bioelectrical impedance analysis (BIA) with the Tanita BC-418 body composition analyzer and expressed in kilograms (kg). Fat-free mass represents total body mass excluding fat mass. Changes in fat-free mass from baseline throughout the intervention will be evaluated. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Gastrointestinal Symptom Rating Scale Score | Baseline (Week 0), Week 4, and Week 8. | Gastrointestinal symptoms will be assessed using the Turkish-adapted and validated version of the Gastrointestinal Symptom Rating Scale (GSRS) (Turan et al., 2017). The scale consists of 15 items rated on a 7-point Likert scale (1-7), covering five symptom domains: abdominal pain, reflux, indigestion, diarrhea, and constipation. Higher scores indicate more severe gastrointestinal symptoms. Total and/or domain scores will be evaluated according to the scale scoring guidelines. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Pittsburgh Sleep Quality Index Score | Baseline (Week 0), Week 2, Week 4, Week 6, and Week 8. | Sleep quality will be assessed using the Turkish-adapted and validated version of the Pittsburgh Sleep Quality Index (PSQI) (Ağargün et al., 1996). The questionnaire consists of 10 main questions and evaluates seven components of sleep quality. Each component is scored from 0 to 3, yielding a global score ranging from 0 to 21. Higher scores indicate poorer sleep quality, and scores greater than 5 indicate poor sleep quality. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Total Cholesterol Levels | Baseline (Week 0) and Week 8. | Total cholesterol levels will be measured in fasting venous blood samples and expressed in milligrams per deciliter (mg/dL). Changes in total cholesterol levels from baseline to the end of the intervention will be evaluated. | ClinicalTrials.gov |
| Secondary | Change from Baseline in LDL Cholesterol Levels | Baseline (Week 0) and Week 8. | Low-density lipoprotein cholesterol (LDL-C) levels will be measured in fasting venous blood samples and expressed in milligrams per deciliter (mg/dL). Changes in LDL-C levels from baseline to the end of the intervention will be evaluated. Higher levels generally indicate a less favorable lipid profile. | ClinicalTrials.gov |
| Secondary | Change from Baseline in HDL Cholesterol Levels | Baseline (Week 0) and Week 8. | High-density lipoprotein cholesterol (HDL-C) levels will be measured in fasting venous blood samples and expressed in milligrams per deciliter (mg/dL). Changes in HDL-C levels from baseline to the end of the intervention will be evaluated. Higher levels generally indicate a more favorable lipid profile. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Triglyceride Levels | Baseline (Week 0) and Week 8. | Triglyceride levels will be measured in fasting venous blood samples and expressed in milligrams per deciliter (mg/dL). Changes in triglyceride levels from baseline to the end of the intervention will be evaluated. Higher levels indicate an unfavorable lipid profile. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Fasting Blood Glucose Levels | Baseline (Week 0) and Week 8. | Fasting blood glucose levels will be measured in venous blood samples after at least 8 hours of fasting and expressed in milligrams per deciliter (mg/dL). Changes in fasting blood glucose levels from baseline to the end of the intervention will be evaluated. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Fasting Insulin Levels | Baseline (Week 0) and Week 8. | Fasting insulin levels will be measured in venous blood samples after at least 8 hours of fasting and expressed in microinternational units per milliliter (μIU/mL). Changes in fasting insulin levels from baseline to the end of the intervention will be evaluated. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Glycated Hemoglobin (HbA1c) Levels | Baseline (Week 0) and Week 8. | Glycated hemoglobin (HbA1c) levels will be measured in venous blood samples and expressed as a percentage (%). HbA1c reflects average blood glucose levels over approximately the previous 2-3 months. Changes in HbA1c levels from baseline to the end of the intervention will be evaluated. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) | Baseline (Week 0) and Week 8. | Insulin resistance will be assessed using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated using fasting insulin (μIU/mL) and fasting blood glucose (mg/dL) concentrations. HOMA-IR will be calculated as fasting insulin multiplied by fasting blood glucose divided by 405. Higher HOMA-IR values indicate greater insulin resistance. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Alanine Aminotransferase (ALT) Levels | Baseline (Week 0) and Week 8. | Alanine aminotransferase (ALT) levels will be measured in venous blood samples and expressed in units per liter (U/L). Changes in ALT levels from baseline to the end of the intervention will be evaluated. Elevated ALT levels may indicate hepatocellular injury. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Aspartate Aminotransferase (AST) Levels | Baseline (Week 0) and Week 8. | Aspartate aminotransferase (AST) levels will be measured in venous blood samples and expressed in units per liter (U/L). Changes in AST levels from baseline to the end of the intervention will be evaluated. Elevated AST levels may indicate tissue injury, including liver or muscle injury. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)